Botanix Pharma Issues New Shares and Advances Dermatology Pipeline

Botanix Pharmaceuticals Limited (AU:BOT) has released an update.

Botanix Pharmaceuticals Limited has issued over 3.4 million new shares, which are now available for immediate trading, following the exercise of equivalent unquoted options. The company, a pioneer in dermatological treatments, recently received FDA approval for Sofdra™, a novel product for primary axillary hyperhidrosis, and is advancing a pipeline of late-stage clinical products for various skin conditions.

For further insights into AU:BOT stock, check out TipRanks’ Stock Analysis page.